References
- FerraraNHillanKJGerberHPDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov2004339140015136787
- MichelsSRosenfeldPJPuliafitoCASystemic bevacizumab (Avastin) therapy for neo-vascular age related macular degeneration: twelve-week results of an uncontrolled open-label studyOphthalmology20051121035107415936441
- HurwitzHSainiSBevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse eventsSemin Oncol200633S26S3417145522
- GotlibVKhaledSLapkoISkin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to responseAnticancer Drugs2006171227122917075324
- MotlSBevacizumab in combination chemotherapy for colorectal and other cancersAm J Health Syst Pharm2005621241
- GordonMSMargolinKTalpazMPhase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol20011984385011157038
- FungAERosenfeldPJReichelEThe International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBr J Ophthalmol2006901344134916854824
- CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med200435133734515269313
- RatainMJEisenTStadlerWMPhase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal carcinomaJ Clin Oncol2006242505251216636341